Latest News
Lupin announces receipt of US FDA tentative approval for Apixaban Oral Suspension
28 September 2026 - Pharmaceutical company Lupin Limited (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) reported on Monday that it has received tentative US Food and Drug Administration approval for its New Drug Application for Api...
QIAGEN completes US QIAstat-Dx bloodstream infection portfolio with FDA clearance
28 September 2026 - Netherlands-based holding company QIAGEN N.V. (NYSE:QGEN) (Frankfurt Prime Standard:QIA) announced on Monday that it has received US Food and Drug Administration (FDA) clearance for a new QIAstat-Dx panel, giving US laboratories a...
4basebio announces Phase I cell therapy programme partnership with TriLink
28 September 2026 - Cambridge-based biotechnology company 4basebio PLC (AIM: 4BB) reported on Monday that it is to supply clinical-grade opDNA synthetic DNA for a multinational pharmaceutical company's Phase I cell therapy programme, extending a...
Kodiak Sciences to present topline Phase 3 study results for Zenkuda and KSI-501 in wet AMD
28 September 2026 - Kodiak Sciences Inc (Nasdaq:KOD), a precommercial retina-focused biotechnology company, said on Friday that the company will report topline results from DAYBREAK, a Phase 3 study evaluating both Zenkuda (tarcocimab tedromer) and K...
IASO Bio presents first-in-human data of BCMA-targeted in vivo CAR-T cell therapy IASO206 at 2026 IMS
28 September 2026 - Chinese commercial-stage biopharmaceutical company IASO Biotechnology (IASO Bio) announced on Saturday the presentation of first-in-human (FIH) Phase 1 clinical data for IASO206, its internally developed BCMA-targeted in vivo CAR-...